



Press Release

Montrouge, France, June 16, 2022

DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, and Dr. Pharis Mohideen, Chief Medical Officer, will participate in a fireside chat on Thursday, June 16, 2022, at 12:00 p.m. ET at the JMP Securities Life Sciences Conference in New York.

A webcast of the presentation will be available on the Investors & Media section of the Company's website: <https://www.dbv-technologies.com/investor-relations/>

A replay of the presentation will also be available on DBV Technologies' website after the event.

About DBV Technologies

DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies' food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact

Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact

Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com